Shield Therapeutics Share Discussion Threads

[purchaseatthetop] 21/2/2024 09:59

The MMs just set the offer at 3p on opening and therefore all the sells as the price dropped after opening appeared as buys. Until trades 180 odd where they started changing the offer but still it was wrong. Just ignore the buy/sell figures as they are miles off. The share price tanked because loads were sold. That’s it. Nothing to do with a cash raise.

[little minx] 21/2/2024 09:51

Can't trust the buys and sells as all mixed up although I believe there are lots of buyers at this price

[pwhite73] 21/2/2024 09:43

54m buys to 7m sells. A 10m at 3p and the price is still not moving. There can only be two reasons for this. The company is replenishing its depleted cash reserves with a forward sold heavily discounted placing at about 2.5p or a significant holder is selling out and not cleared yet.

If it's the first the price will remain where it is or lower. If it's the second then it will bounce back when the seller is gone.

[puphead] 21/2/2024 09:32

* $10mil /Q not per month

[zen12] 21/2/2024 09:29

Stupid drop by MMs...should be back up soon.

[tripletop1] 21/2/2024 09:15

Cavendish update:

Total reported revenues and other income were $17.5m (our forecast $16m) in 2023 vs $5.5m in 2022. The composition of that revenue was different to our expectations such that Accrufer US revenues of $11.6m compared with $3.6m in 2022 but came in below our estimate of $13.6m. In the release, the company has noted that the methodology used by the third-party data provider for US Accrufer scrips has resulted in an overstatement for 2023. Revised figures for 2023 have been given showing 77,000 total scrips as opposed to 90,500 under the previous methodology (and the Cavendish forecast of 93,000). Accrufer’s net selling price in H2 2023 of $145 in H2 2023 was an increase of 21% to that seen in H1 2023, with Q4 being stable vs Q3. Total cash at the end of 2023 was $13.9m and the company has indicated that it should turn cash flow positive in H2 2025, vs the previous target of end 2024. OpEx management controls will be put in place to preserve cash. With a new CFO starting in January 2023 and this revision of US scrips taking place, we are placing our forecasts and target price under review.

[hamidahamida] 21/2/2024 09:15

The company that has been telling porkies Making up numbers Go read the RNS history

[best1467] 21/2/2024 09:14

Good point was the 17.5million YE included the Viatris staging fee of 5million if it didn’t then they need around 5.5 million in this quarter which at current growth should be possible

[beatme1] 21/2/2024 09:13

Overdone here

[beatme1] 21/2/2024 09:13

Bought 1m shares

[hamidahamida] 21/2/2024 09:12

Maybe you don't like hearing the truth

[sicilian_kan] 21/2/2024 09:02

Two quick points.

1) Shareholders turned down a 6.2p offer last year! How they might come to regret that.

2) Look at the RNS for 28 September re the $20m secured loan facility. Covenants apply. They must have Group revenue of US$22.5m for the 12 months trailing end Q1 24. What is the chance of them missing that this Q?

[qipincha] 21/2/2024 08:53

Thanks mally6
Shield Therapeutics hails breakthrough year

[sclper] 21/2/2024 08:53

Looks like they burnt through the $26million raised in September very quickly ?

[mally6] 21/2/2024 08:50

https://www.proactiveinvestors.co.uk/companies/news/1041412/shield-therapeutics-hails-breakthrough-year-1041412.html

[hamidahamida] 21/2/2024 08:48

This management has a history of doing surprise deeply discounted preemptive placings Sp right now is around 3p they can pull one off and raise 10 million issuing 1billion shares at 1p.

[qipincha] 21/2/2024 08:48

this is overdone.
after all, the company has $4.3m revenue in Q4
though there is a risk
it has already been priced in.

[mally6] 21/2/2024 08:44

Result don't look too bad is this overdone or a falling knife

[jasonpugh] 21/2/2024 08:42

Help. Man the lifeboats. 🤣. Sold mine in feb 2022 for 29p. Been waiting patiently. Should I buy at sub 3p. You better believe it. This share has been good for me. DYOR

[purchaseatthetop] 21/2/2024 08:38

Qipincha. They are going to run out of cash very soon and will have to raise well before that happens.

[hamidahamida] 21/2/2024 08:38

Deeply discounted placing coming soon Get out whilst you can

[hamidahamida] 21/2/2024 08:36

At the time of September placing company said Average cash burn figure was 3.3 million Assuming that burn rate they have already burnt through further 6 million+ What's left at the end of February about 7/8millionDeeply Placing is coming sooner than you think